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Abstract 14 
 15 
Background 16 
Repeated culture reduces within-sample Mycobacterium tuberculosis genetic diversity due 17 
to selection of clones suited to growth in culture and/or random loss of lineages, but it is 18 
not known to what extent omitting the culture step altogether alters genetic diversity. We 19 
compared M. tuberculosis whole genome sequences generated from 39 paired clinical 20 
samples. In one sample DNA was extracted directly from sputum then enriched with 21 
custom-designed SureSelect (Agilent) oligonucleotide baits and in the other it was extracted 22 
from mycobacterial growth indicator tube culture. 23 
 24 
Results 25 
DNA directly sequenced from sputum showed significantly more within-sample diversity 26 
than that from mycobacterial growth incubator tube culture. This was demonstrated by 27 
more variants present as heterozygous alleles (HAs) where both a variant and wild type 28 
allele were present within a given sample (p<0.001) and greater within-sample Shannon 29 
diversity (p<0.001). Seven genes with high within-sample diversity have previously been 30 
identified as targets for positive selection, highlighting their potential role in adaptation to 31 
survival within the host and under drug pressure. Resistance associated variants present as 32 
HAs occurred in six patients, and in four cases may have provided a genotypic explanation 33 
for phenotypic resistance.  34 
 35 
Conclusions 36 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/446849doi: bioRxiv preprint first posted online Oct. 18, 2018; 
 3
Culture-free M. tuberculosis whole genome sequencing detects more within-sample 37 
diversity and may allow detection of mycobacteria that are not actively replicating. 38 
 39 
Key words: Mycobacterium tuberculosis; drug-resistant tuberculosis; whole genome 40 
sequencing; sputum; within-patient diversity; heteroresistance  41 
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Background 42 
 43 
International efforts to reduce tuberculosis (TB) infections and mortality over the last two 44 
decades have only been partially successful. In 2017, 10 million people developed TB and it 45 
has overtaken HIV as the infectious disease responsible for the most deaths worldwide(1, 46 
2). Drug resistance is a major concern with a steady rise in the number of reported cases 47 
globally and rapid increases in some areas(1). Patients with Mycobacterium tuberculosis 48 
resistant to the first line drugs rifampicin and isoniazid are classed as having multidrug-49 
resistant (MDR) TB and usually treated with a standardised second-line drug regimen for at 50 
least nine months, which is also used for rifampicin monoresistance(3, 4). With the 51 
emergence of resistance to fluoroquinolones and aminoglycosides (extensively drug-52 
resistant [XDR] TB) there is an increasing need for individualised therapy based on drug 53 
susceptibility testing (DST). Individualised therapy ensures patients are treated with 54 
sufficient active drugs which can prevent selection of additional resistance, improve 55 
treatment outcomes and reduce duration of infectiousness(5-8). 56 
 57 
Traditionally, phenotypic culture-based DST was used to identify drug resistance but this is 58 
being replaced by rapid genetic tests that detect specific drug resistance conferring 59 
mutations. Next generation whole genome sequencing (WGS) of M. tuberculosis is being 60 
increasingly used in research and clinical settings to comprehensively identify all drug 61 
resistance associated mutations(9). M. tuberculosis has a conserved genome with little 62 
genetic diversity between strains(10), but more detailed analysis of individual patient 63 
samples with WGS has identified genetically separate bacterial subpopulations in sequential 64 
sputum samples(11-15) and across different anatomical sites(16). This within-patient 65 
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diversity can occur as a result of mixed infection with genetically distinct strains or within-66 
host evolution of a single infecting strain(17).  67 
 68 
Bacterial subpopulations can be detected in clinical samples after sequencing reads are 69 
mapped to a reference genome where multiple base calls are detected at a single genomic 70 
site. These heterozygous alleles (HAs) at sites associated with drug resistance (resistance 71 
associated variants, RAVs) may reflect heteroresistance, where a fraction of the total 72 
bacterial population is drug susceptible while the remainder is resistant(18). Identification 73 
of genetic diversity within clinical samples is important as it may improve detection of RAVs 74 
over currently available genetic tests and consensus-level WGS(18). Identifying RAVs could 75 
improve individualised therapy, prevent acquired resistance(12), and give insight into 76 
bacterial adaptation to the host.  77 
 78 
M. tuberculosis WGS is usually performed on cultured isolates to obtain sufficient purified 79 
mycobacterial DNA. However, the culture process can change the population structure from 80 
that of the original sample due to genetic drift (random loss of lineages) and/or the 81 
selection of subpopulations more suited to growth in culture(19-21), and repeated 82 
subculture leads to loss of genetic diversity and heteroresistance(22). Additionally, in the 83 
normal course of M. tuberculosis infection, some bacteria exist as viable non-culturable 84 
persister organisms that are hypothesised to cause the high relapse rate seen following 85 
treatment of insufficient duration(23). These organisms are likely to be missed by any 86 
sequencing method reliant on culture. 87 
 88 
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WGS directly from sputum without enrichment is challenging(24). It has recently been 89 
improved by depleting human DNA during DNA extraction(25). We have previously reported 90 
the use of oligonucleotide enrichment technology SureSelect
 
(Agilent, CA, USA) to sequence 91 
M. tuberculosis DNA directly from sputum(26) and demonstrated its utility in determining a 92 
rapid genetic drug resistance profile(27, 28).  93 
 94 
It remains unclear to what extent WGS of cultured M. tuberculosis samples underestimates 95 
the genetic diversity of the population in sputum samples. One previous study of 16 patients 96 
did not identify increased genetic diversity in M. tuberculosis DNA sequenced directly from 97 
sputum compared to DNA from culture(25), whereas another study of mostly drug 98 
susceptible patients showed sequencing directly from sputum identified a slight excess of 99 
HAs relative to culture(27). Here we reanalyse heterozygous alleles (HAs) present in that 100 
study(27) in addition to newly collected samples from patients with MDR-TB, use a more 101 
sensitive analysis to measure overall within-sample genetic diversity and further explore the 102 
genomic location of the additional diversity identified. 103 
 104 
Results 105 
 106 
Patient Characteristics and Drug Susceptibility Testing 107 
 108 
Whole genome sequences were obtained for 39 patients from both mycobacterial growth 109 
indicator tube (MGIT) culture and direct sputum sequencing. The patients were 110 
predominantly of black African ethnicity (80%) and 50% were HIV positive (Table 1). First-111 
line phenotypic drug susceptibility testing (DST) results identified 22 patients with MDR-TB 112 
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 7
and two with rifampicin monoresistance. In addition there were three isoniazid 113 
monoresistant patients and ethambutol resistance was detected in 8 patients. Second-line 114 
phenotypic DST was performed for patients with rifampicin-resistant or MDR-TB and 115 
identified one case of kanamycin resistance (Table 2). 116 
 117 
We observed greater median coverage depth in sputum-derived sequences than MGIT 118 
sequences (164.3 vs 136.6, p=0.068). A genotypic susceptibility profile was determined by 119 
evaluating MGIT WGS for consensus-level RAVs using a modified version of a publicly 120 
available list(29). Genotypic RAVs predicted all rifampicin phenotypic resistance and >90% of 121 
isoniazid phenotypic resistance. Ethambutol genotypic RAVs were poorly predictive of 122 
phenotypic resistance in line with findings from other studies(30) (Table 2). The patient with 123 
kanamycin phenotypic resistance was correctly identified by an rrs a1401g RAV. No full 124 
phenotypic fluoroquinolone phenotypic resistance was identified, but several colonies from 125 
patient F1013 did grow in the presence of ofloxacin (although not enough to be classified as 126 
resistant). The consensus sequences from this patient harboured a gyrB E501D mutation 127 
which is believed to confer resistance to moxifloxacin but not other fluoroquinolones, which 128 
may explain the borderline phenotypic DST result(31). 129 
 130 
Genetic Diversity 131 
 132 
To compare consensus sequences from sputum and MGIT, a WGS consensus sequence-level 133 
maximum likelihood phylogenetic tree was constructed (Supplementary Material: Figure 1). 134 
Four previously sequenced strains from KwaZulu-Natal were included(32). As expected, all 135 
paired sequences were closely related, with a mean difference of 1.30 (range 0-9) single 136 
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nucleotide polymorphisms (SNPs). Samples from patients F1066 and F1067 were closely 137 
related with only one consensus-level SNP separating all four consensus sequences. There 138 
was no obvious epidemiological link between these patients (although this study was not 139 
designed to collect comprehensive epidemiological information) and they lived 20km apart 140 
in Durban. However, both patients were admitted contemporaneously to an MDR 141 
treatment facility and sampled on the same day. DNA extraction and sequencing occurred 142 
on different runs so the close genetic linkage may represent direct transmission within a 143 
hospital setting, a community transmission chain or an unlikely cross-contamination during 144 
sample collection. 145 
 146 
Having established congruence between sputum and MGIT sequences at the consensus 147 
level we then compared genetic diversity by DNA source. We first defined a threshold for 148 
calling variants present as heterozygous alleles (HAs) in our entire dataset by using a range 149 
of minimum read count frequencies as described in the methods (Figure 1). Below a 150 
minimum of five supporting reads there was an exponential increase in the number of HAs 151 
identified, which may be indicative of the inclusion of sequencing errors. To reduce this risk, 152 
we used a threshold of a minimum of five supporting reads. 153 
 154 
Genetic diversity may occur because of within-host evolution or mixed infection. To identify 155 
mixed infection we used a molecular barcode(33) to scan all HAs for a panel of 413 156 
phylogenetic SNPs that can resolve M. tuberculosis into one of seven lineages and 55 sub-157 
lineages. We found three phylogenetic SNPs among the HAs. In all cases the heterozygous 158 
phylogenetic SNP originated from the same sublineage as other SNPs present at 100% 159 
frequency, and there were no cases of HAs indicating the presence of more than one lineage 160 
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or sublineage. This suggests that the genetic diversity identified is mostly or exclusively due 161 
to within-host evolution, although there remains a small possibility that mixed infections 162 
with two strains from the same sub-lineage could have occurred. 163 
 164 
As a first step to comparing diversity between sputum and MGIT sequenced samples we 165 
looked at the location of genetic diversity within the M. tuberculosis genome. Variants were 166 
called in the MGIT and sputum sequences for each patient and classified as present in MGIT 167 
only, sputum only or shared (present in both). HAs were widely dispersed across the 168 
genome at similar sites in both sputum and MGIT samples but some genes had multiple HAs 169 
(Table 3). The highest genetic diversity was found in the ribosomal RNA (rRNA) genes (rrs 170 
and rrl) with 358 HAs, of which 98.6% were only found in sputum-derived sequences.  171 
 172 
As rRNA contains regions that are highly conserved across bacteria, it was considered a 173 
possibility that SureSelect baits targeting rRNA genes were capturing both M. tuberculosis 174 
and other bacterial species. To evaluate this, metagenomic assignment was performed on 175 
all reads. Sampling reads not assigned to M. tuberculosis (i.e. presumed contaminants from 176 
other bacteria) and performing a BLAST search against M. tuberculosis 16S and 23S rRNA 177 
genes indicated that a sizeable proportion of these reads from directly sequenced sputum 178 
had a BLAST hit of at least 30 bases (median 11% v 0% of equivalent reads from MGIT 179 
sequencing, p<0.001, Supplementary Material: Figure 2). The taxonomic assignment of 180 
these reads were indeed typical of genera composing the oral flora, with a high 181 
representation of Actinomyces, Fusobacterium, Prevotella, and Streptococcus 182 
(Supplementary Material: Figure 3).  183 
 184 
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This supported the hypothesis that the baits may enrich rRNA from other organisms so rRNA 185 
genes were excluded from further analysis. The difference in diversity between sputum and 186 
MGIT sequences can be explained by the selective nature of MGIT media which will enrich 187 
M. tuberculosis sequences. Importantly the frequency of HAs in other highly diverse genes 188 
between sequencing strategies was more balanced (Table 3). Pertinently seven of these 189 
genes (Rv1319c(34), lppB(35), Rv2082(35), ppsA(34, 36), ponA1(36), lppA(37), and pks12(35, 190 
36)) with high numbers of HAs have been previously identified as highly diverse in 191 
comparative genomic studies suggesting the detected HAs are not artefactual. The 192 
frequencies at which HAs in these genes were present in MGIT and sputum is shown in 193 
Supplementary Material Figure 4. 194 
 195 
After confirming the absence of mixed infections and removing rRNA gene sequences we 196 
compared the frequency of HAs in sputum and MGIT. There were 2048 variants across the 197 
dataset that were present as a HA in either MGIT, sputum or both sequences (Table 4). 198 
Variants present in both MGIT and sputum derived sequences were more likely to be 199 
present as a HA in the sputum-derived sequence (3.2% v 1.9%, p<0.0001). Of the other 200 
variants present as HAs, 821 were unique to direct sputum sequencing and 153 were unique 201 
to MGIT sequencing (Table 4). Variants found only in sputum were more likely to be 202 
heterozygous than those found only in MGIT or in both (p<0.0001). The distribution of HAs 203 
by patient is shown in Figure 2A. HAs found only by one modality were more likely to be 204 
SNPs than shared HAs, where the majority were insertions or deletions. The ratio of non-205 
synonymous to synonymous HAs was similar for those that were shared or MGIT only, but 206 
was lower for sputum only HAs. Frameshift mutations were most prevalent among shared 207 
HAs (Table 4). 208 
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 209 
To confirm our findings of increased diversity in sputum we calculated mean within-sample 210 
diversity (H), excluding rRNA genes and repeat regions (see methods). The mean diversity 211 
was significantly greater in sputum than MGIT-derived sequences (Figure 2B: 0.116±0.078 v 212 
0.054±0.026 , mean H
sputum
/H
MGIT
 = 2.66, p=3.0 x 10
-5
).   213 
 214 
Genetic diversity in drug resistance genes 215 
 216 
HAs in drug resistance-associated regions, including promoters and intergenic regions, were 217 
individually assessed. Five of the 39 patients had RAVs present as HAs in at least one gene, 218 
which are shown in Table 5. F1002 had three compensatory mutations in rpoC present at 219 
HAs in both sequences. F1007 had high-level phenotypic isoniazid resistance despite wild 220 
type katG and inhA genes, but did have two ahpC promoter variants present as HAs. Neither 221 
of these variants are reported frequently but both have been previously associated with 222 
resistance in limited numbers of samples(38). As described above F1066 and F1067 were 223 
highly related with only one consensus SNP difference between all four sequences. Both had 224 
phenotypic high level isoniazid resistance with no consensus-level katG or inhA mutation, 225 
but had frameshift katG mutations present as HAs which have the potential to cause 226 
resistance(39). F1066 and RF021 had Rv1979c and pncA mutations respectively at low 227 
frequency in sputum only which have the potential to confer phenotypic resistance to 228 
clofazimine (Rv1979c) and pyrazinamide (pncA), although no phenotypic testing was 229 
performed for these drugs.  230 
 231 
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Discussion 232 
 233 
In this study we whole genome sequenced DNA from sputum and MGIT culture in paired 234 
samples from 39 patients and compared within-patient genetic diversity of the bacterial 235 
genome identified from each source. All paired sequences were closely related at the 236 
consensus level, and WGS predicted phenotypic drug susceptibility with over 90% sensitivity 237 
and specificity for rifampicin and isoniazid in line with published data(40).  238 
 239 
The understanding of within-patient M. tuberculosis genetic diversity is becoming 240 
increasingly important as the detection of rare variants has been shown to improve the 241 
correlation between phenotypic and genotypic drug resistance profiles(18) and can identify 242 
emerging drug resistance(11, 12). Here we have demonstrated that significantly more 243 
genetic diversity is identified by WGS performed directly from enriched sputum than MGIT 244 
culture. Not including a culture step avoids the introduction of bias towards culture-adapted 245 
subpopulations and the impact of random chance and is also likely to incorporate DNA from 246 
viable non-culturable mycobacteria. A reduction in genetic diversity has previously been 247 
shown with sequential M. tuberculosis subculture(19, 22), but was not confirmed by a study 248 
performing WGS directly from sputum(25). However, the 16 paired sputum and MGIT 249 
samples compared by Votintseva(25) had a minimum of 5x coverage compared to a 250 
minimum 40x coverage in this study, and were likely to contain less genetic material as they 251 
were surplus clinical rather than dedicated research samples.  252 
 253 
We found that the rRNA genes have high levels of diversity in sputum samples, but believe 254 
this is due to non-mycobacterial DNA hybridising to the capture baits — a conclusion borne 255 
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out by the taxonomic assignment of reads aligning to these genes in common oral bacteria. 256 
We therefore exclude these from further analysis, and recommend others using enrichment 257 
from sputum do similarly. We use two methods to evaluate within-sample M. tuberculosis 258 
genetic diversity. First, we demonstrate increased diversity when sequencing directly from 259 
sputum with significantly more unique heterozygous alleles (HAs) than sequencing from 260 
MGIT culture. We also observed significantly higher genetic diversity in sputum-derived 261 
sequences by comparing the Shannon diversity of variable sites across pairs of samples.  262 
 263 
Many of the genes with high levels of within-sample diversity are also reported to be targets 264 
for convergent evolution, independently accumulating similar mutations on a global scale. 265 
This implies that diversity seen on a macroevolutionary scale has a basis in microevolution, 266 
and reinforces the importance of accurately characterising the biological function of these 267 
genes and their products to aid the identification of new therapeutic targets. Two-thirds of 268 
the patients with MDR-TB had already been treated for drug-sensitive TB, and the diversity 269 
identified in sputum samples may therefore represent early adaptation to drug pressure. 270 
Importantly, as direct sputum sequencing does not rely on live mycobacteria, DNA from 271 
recently killed M. tuberculosis is likely to also be sequenced, meaning that recent genomic 272 
mutations are likely to be represented as HAs. 273 
 274 
In four patients, RAVs present as HAs provided a likely genotypic basis for otherwise 275 
unexplained phenotypic resistance. Given the small total number of resistance mutations in 276 
this study, the excess of heterozygous known RAVs in directly sequenced sputum is not 277 
statistically significant. However the presence of heterozygous RAVs in both MGIT and 278 
sputum sequences reinforces the biological importance of these mutations. 279 
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 280 
A limitation of this study is that it can be difficult to distinguish low frequency variants from 281 
sequencing error. Ideally low frequency variants could be confirmed by resequencing the 282 
same DNA samples. To reduce the risk of sequencing errors yet still identify genetic diversity 283 
we used the lowest minimum read threshold at which the number of HAs remained stable. 284 
Also, it is reassuring that of all fixed and heterozygous variants called, more than 93% were 285 
identified from both DNA sources.  286 
 287 
Conclusions 288 
 289 
Directly sequencing M. tuberculosis from sputum is able to identify more genetic diversity 290 
than sequencing from culture. Understanding within-patient genetic diversity is important 291 
to understand bacterial adaptation to drug treatment and the acquisition of drug resistance. 292 
It also has potential to identify low frequency RAVs that may further enhance genotypic-293 
phenotypic drug resistance correlation. 294 
 295 
Methods 296 
 297 
Patient enrolment 298 
Adult patients presenting with a new diagnosis of sputum culture-positive TB were included 299 
in the study. Patients were recruited in London, UK (n=15) and Durban, South Africa (n=24). 300 
All patients recruited in Durban were Xpert MTB/RIF (Cepheid, CA, USA) positive for 301 
rifampicin resistance. Two sputum samples were collected prior to initiating treatment, with 302 
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one inoculated into mycobacterial growth indicator tube (MGIT) culture (BD, NJ, USA) and 303 
the other used for direct DNA extraction.  304 
 305 
Ethics, Consent and Permissions 306 
 307 
All patients gave written informed consent to participate in the study. Ethical approval for 308 
the London study was granted by NHS National Research Ethics Service East Midlands–309 
Nottingham 1 (reference 15/EM/0091). Ethical approval for the Durban study was granted 310 
by University of KwaZulu-Natal Biomedical Research Ethics Committee (reference 311 
BE022/13). 312 
 313 
Microbiology 314 
MGIT samples were incubated in a BACTEC MGIT 960 (BD, NJ, USA) until flagging positive. 315 
Phenotypic DST data for London samples were those provided to treating hospitals by Public 316 
Health England. Phenotypic DST for Durban samples was performed using the solid agar 317 
proportion method (Supplementary Material: Methods). 318 
 319 
DNA extraction and sequencing 320 
Positive MGIT tubes were centrifuged at 16,000g for 15 minutes and the supernatant 321 
removed. Cells were resuspended in phosphate-buffered saline before undergoing heat 322 
killing at 95°C for 1 hour followed by centrifugation at 16,000g for 15 minutes. The 323 
supernatant was removed and the sample resuspended in 1mL sterile saline (0.9% w/v). The 324 
wash step was repeated. DNA was extracted with mechanical ribolysis before purification 325 
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with DiaSorin Liaison Ixt (DiaSorin, Italy) or CTAB(41). NEBNext Ultra II DNA (New England 326 
Biolabs, MA, USA) was used for DNA library preparation.  327 
 328 
Sputum samples for direct sequencing were similarly heat killed processed as for MGIT 329 
samples. DNA extraction was performed with mechanical ribolysis followed by purification 330 
using DiaSorin Liaison Ixt (DiaSorin, Italy) or DNeasy blood & tissue kit (Qiagen, 331 
Germany)(41). Target enrichment was performed using SureSelect with a custom-designed 332 
bait set providing coverage of the entire M. tuberculosis genome as described 333 
previously(27). Batches of 48 multiplexed samples were sequenced on a NextSeq (Illumina, 334 
CA, USA). 335 
 336 
Bioinformatic analysis 337 
Bioinformatic analysis was performed with CLC Genomics Workbench v11.0 (Qiagen, 338 
Germany). DNA sequence reads were aligned to an H37Rv reference genome as detailed in 339 
the Supplementary Material Methods section (GenBank accession NC_000962.3). All 340 
samples had minimum 98% 1x reference genome coverage and mean coverage depth 40x 341 
across the genome. Variants falling within or near hypervariable elements were excluded 342 
(Supplementary Material: Table 1). A consensus sequence was extracted and used to 343 
determine the genotypic drug susceptibility profile. To construct the maximum likelihood 344 
phylogenetic tree, variants were called against the reference genome using VarScan v2.3.9 345 
(Supplementary Material: Methods). 346 
 347 
For the initial analysis of genetic diversity, variants were included if supported by ≥2 reads, 348 
with ≥1 forward and reverse read. The minimum supporting read threshold was increased in 349 
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a stepwise fashion from 2 to 20. Further analyses were performed on variant tracks where 350 
variants were supported ≥5 supporting reads including ≥1 forward and reverse read.  351 
 352 
To compare diversity between paired samples, we first mapped reads to the reference 353 
genome using bwa mem v0.7.12(42). After verifying all samples had adequate coverage with 354 
qualimap(43) (mean ± standard deviation coverage at 10x: 98.0 ± 1.8%) and realigning 355 
indels, variants were called with HaplotypeCaller in GATK v3.3.0(44) (Supplementary 356 
Material: Methods). The gvcf files were combined for each pair of samples with 357 
CombineGVCFs in GATK then screened to remove sites in variable regions and rRNA genes 358 
with vcfintersect in vcflib, resulting in 39 paired gvcf files containing allele depths at variable 359 
positions for diversity analysis.  360 
 361 
Metagenomic assignment 362 
Sequencing reads were classified using Kraken v0.10.6(45) against a custom Kraken 363 
database previously constructed from all available RefSeq genomes for bacteria, archaea, 364 
viruses, protozoa, and fungi, as well as all RefSeq plasmids (as of September 19
th
 2017) and 365 
three human genome reference sequences(46). The size of the final database after shrinking 366 
was 193 Gb, covering 38,190 distinct NCBI taxonomic IDs.  367 
 368 
To assess the proportion of contaminating reads that could generate spurious diversity 369 
when mapped to M. tuberculosis ribosomal genes, we randomly subsampled 100 reads 370 
taxonomically assigned as non-M. tuberculosis and performed a BLAST search with blastn 371 
v2.2.28(47) against rRNA genes from the H37Rv reference genome. We only analysed hits of 372 
at least 30 bases. 373 
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 374 
Statistics 375 
Statistical analyses were performed with Prism v7.0 (Graphpad, CA, USA). The number of 376 
HAs in paired samples were compared using a two-tailed Wilcoxon matched-pairs signed 377 
rank test. Numbers of HAs found between groups were compared with chi-squared. 378 
 379 
Within-sample diversity ( ) was calculated using Shannon diversity from the allele 380 
frequencies (). The Shannon index ( 
 
) expresses the positional entropy at each position 381 
(), with the mean positional entropy ( ) indicating greater within-sample diversity:  382 
     
 

 
  
 ,
 log 

 ,

,,,	
 
 
To make a fair comparison for each pair of samples, after removing indels, sites were 383 
included if they contained a variant in at least one and had a depth coverage 30 in both. 384 
We found that the depth coverage cutoff had no qualitative effect on the conclusions. The 385 
difference in mean within-sample diversity depending on DNA source was compared with a 386 
two-tailed Wilcoxon matched-pairs signed rank test. 387 
 388 
Abbreviations 389 
 390 
DST drug susceptibility testing 
HA heterozygous allele 
MDR-TB multidrug resistant-tuberculosis 
MGIT mycobacterial growth indicator tube 
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RAV resistance-associated variant 
rRNA ribosomal RNA 
SNP single nucleotide polymorphism 
TB tuberculosis 
WGS whole genome sequencing 
 391 
 392 
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Tables 432 
 433 
 Count / mean Range/percentage 
Age 36.7 22 – 64 
Male sex 23/37 59.0% 
Ethnicity 
Asian 
Black African 
Caucasian 
 
3/35 
28/35 
4/35 
 
8.6% 
80.0% 
11.4% 
HIV positive 
CD4 count (median) 
On antiretroviral therapy at time of diagnosis 
19/38 
296.5* 
8/19** 
50.0% 
17 – 707 
42.1% 
 434 
Table 1. Baseline patient characteristics for 39 patients (or as otherwise specified where 435 
data were missing). *Data missing for 1 patient. 436 
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 438 
Drug 
Resistance by 
phenotypic DST 
Resistance by 
genotypic DST 
Genotypic DST 
sensitivity 
Genotypic DST 
specificity 
First-line drugs 
Rifampicin 24/37 (64.9%) 24/39 24/24 (100%)* 24/24 (100%) 
Isoniazid 25/37 (67.6%) 24/39 23/25 (92.0%) 23/24 (95.8%) 
Ethambutol 8/37 (21.6%) 17/39 8/8 (100%) 8/17 (47.1%) 
Second-line drugs 
Ofloxacin 0/24 (0.0%) 1/24 N/A 0/1 (0%)** 
Kanamycin 1/24 (4.2%) 1/24 1/1 (100%) 1/1 (100%) 
 439 
Table 2. Phenotypic and genotypic drug susceptibility testing (DST) results and sensitivity 440 
and specificity of genotypic DST relative to phenotypic DST. Phenotypic DST available for 441 
first-line drugs for 37 of the 39 patients, and for second-line drugs for 24 patients who 442 
demonstrated rifampicin drug resistance. *In two directly-sequenced sputum samples 443 
rifampicin RAVs were missed due to low coverage, although they were identified in the 444 
corresponding MGIT sample. **This sample had <1% of colonies grow in the presence of 445 
ofloxacin, so is categorised as sensitive but may have low-level or heteroresistance to 446 
fluoroquinolones (see main text). 447 
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Gene 
Heterozygous Allele Count 
Gene 
length 
(base pairs) 
Hypothesised gene 
function 
Shared 
MGIT 
only 
Sputum 
only Total 
rrs 2 3 180 185 3138 23S rRNA 
rrl 0 0 173 173 1537 16S rRNA 
Rv1319c 70 1 24 95 1608 
Metabolism and 
respiration 
lppB 7 6 10 23 663 Surface lipoprotein 
Rv2561 21 0 0 21 294 Unknown function 
Rv3424c 1 1 19 21 363 Unknown function 
Rv2082 16 1 2 19 2166 Unknown function 
ppsA 7 0 11 18 1059 
GGPP synthetase 
(lipid synthesis) 
Rv1435c 3 9 6 18 609 Secreted protein 
ponA1 5 3 9 17 2037 Cell wall biosynthesis 
Rv2277c 2 0 15 17 906 
Metabolism and 
respiration 
vapC31 5 0 12 17 429 Possible toxin 
Rv2823c 5 2 9 16 2430 Unknown function 
lppA 1 3 11 15 660 Surface lipoprotein 
pks12 5 5 4 14 12456 
MPM synthesis (lipid 
metabolism) 
 449 
Table 3. Genes with the most heterozygous alleles (HAs) identified across the entire dataset. 450 
  451 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/446849doi: bioRxiv preprint first posted online Oct. 18, 2018; 
 25
 452 
Shared variants 
MGIT only 
variants 
Sputum only 
variants 
Total 
All variants vs H37Rv (fixed or heterozygous) 
Total variants 33 153 1162 1217 35532 
Variants vs H37Rv present as heterozygous alleles (HAs) only 
Total variants present as 
HAs (% of total variants) 
MGIT 645 (1.9%) 
Sputum 1074 (3.2%) 
153 (13.2%) 821 (67.5%) 2048 (5.8%) 
Median HAs per sample 21 3 15 40 
Variant type (% all HAs) 
SNP 
MNP 
Insertion 
Deletion 
Replacement 
 
500 (46.6%) 
12 (1.1%) 
303 (28.2%) 
259 (24.1%) 
0 (0.0%) 
 
127 (83.0%) 
1 (0.7%) 
8 (5.2%) 
16 (10.5%) 
1 (0.7%) 
 
708 (86.2%) 
24 (2.9%) 
31 (3.8%) 
57 (6.9%) 
1 (0.1%) 
 
1335 (65.2%) 
37 (1.8%) 
342 (16.7%) 
332 (16.2%) 
2 (0.1%) 
Coding change (% all HAs) 
Non-synonymous 
Synonymous 
Intergenic 
 
395 (36.8%) 
159 (14.8%) 
520 (48.4%) 
 
79 (51.6%) 
32 (20.9%) 
42 (27.5%) 
 
318 (38.7%) 
171 (20.8%) 
332 (40.4%) 
 
792 (38.7%) 
362 (17.7%) 
894 (43.7%) 
Non-synon/synon ratio 2.48 2.47 1.86 2.19 
Stop codon (% of all non-
synonymous HAs) 
4 (1.0%) 1 (1.3%) 9 (2.8%) 14 (1.8%) 
Frameshift (% of all non-
synonymous HAs) 
185 (46.8%) 19 (24.1%) 47 (14.8%) 251 (31.7%) 
 453 
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Table 4. Variants identified in MGIT derived, sputum derived, or both sequences from paired 454 
samples. Values given represent totals for the 39 paired samples. SNP = single nucleotide 455 
polymorphism; MNP = multi-nucleotide polymorphism.  456 
  457 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/446849doi: bioRxiv preprint first posted online Oct. 18, 2018; 
 27
 458 
Patient 
ID 
Phenotypic 
resistance 
Mutation 
Frequency 
(MGIT/sputum) 
Description 
F1002 Rifampicin rpoB S450L 100%/100% 
High confidence 
resistance mutation 
F1002 Rifampicin rpoC G332R(48) 82.6%/21.7% 
Putative compensatory 
mutations 
F1002 Rifampicin rpoC L516P(48) 12.7%/7.7% 
F1002 Rifampicin rpoC P1040S(49) 21.7%/12.3% 
F1007 Isoniazid (high) ahpC c-52t(38) 60.0%/50.7% Rare, have been 
associated with 
resistance  
F1007 Isoniazid (high) ahpC g-48a(38) 28.6%/30.3% 
F1061 Rifampicin rpoB H445D 16.1%/0.0%* 
High confidence 
resistance mutation 
F1061 Rifampicin rpoB S450W 84.4%/0.0%* 
High confidence 
resistance mutation 
F1066 Isoniazid (high) katG N218fs 0.0%/6.9% 
Possible resistance 
mutations, not 
previously described 
F1066 
Clofazimine – 
not tested 
Rv1979c G376D 0.0%/0.5% 
F1067 Isoniazid (high) katG N218fs 10.7%/7.6% 
RF021 
Pyrazinamide – 
testing failed 
pncA Q122H 0%/2.5% 
 459 
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Table 5. Resistance-associated variants present as heterozygous alleles (HAs). *These 460 
mutations were also present in sputum but due to low coverage of the area (3 and 4 reads 461 
respectively) variant calling criteria were not met. 462 
 463 
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Figure legends 465 
 466 
Figure 1. Variation in total number of heterozygous alleles (HAs) identified across all 39 467 
patients in sequences generated from sputum and MGIT depending on minimum supporting 468 
read count threshold. Direct sputum samples indicated by red squares, MGIT samples blue 469 
circles. 470 
 471 
Figure 2. (A) Number of heterozygous alleles (HAs) found in directly sequenced sputum only 472 
(sputum), MGIT (MGIT) only or in both samples (shared) by patient. (B) Mean Shannon 473 
diversity at variable positions across pairs of samples (H) as calculated for MGIT and 474 
sputum-derived sequences. Size of point indicates number of variable positions considered 475 
(see Methods). 476 
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